Across TCGA pan-cancer cohorts, ZNF385B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of ZNF385B’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ZNF385B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ZNF385B is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.
LSCC and LUAD are the cancer types where ZNF385B tumor–normal differential expression is most reproducible.